If you take Humira to manage an autoimmune condition, the good news is straightforward: Medicare covers it. Below I’ll walk you through how that coverage works, why your plan might steer you toward a biosimilar, and what the new yearly cap means for a drug like this.
What Humira treats
Humira (the generic name is adalimumab) is a biologic — specifically a TNF blocker, which calms the kind of overactive immune response behind many autoimmune conditions. It’s used for conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.
One detail matters a lot for how Medicare pays: Humira is self-injected at home, not given in a clinic. That’s what determines which part of Medicare covers it.
Brand vs. biosimilar
Humira doesn’t have a traditional generic, but it does have something close: several biosimilars are now available. A biosimilar is a near-copy of the original biologic — highly similar in how it works — and these tend to come at a lower cost and sit on lower tiers. Because of that price difference, plans may prefer or even require a biosimilar, which I’ll cover in a moment.
How Medicare covers it
Because Humira is self-administered at home, it falls under Medicare Part D, the part of Medicare that handles prescription drugs. You get Part D either through a standalone drug plan that pairs with Original Medicare, or built into a Medicare Advantage plan. Original Medicare (Part A and Part B) on its own doesn’t cover drugs you give yourself at home, so having some form of Part D is what makes coverage possible.
As a high-cost biologic, Humira is usually placed on a specialty tier. Every Part D plan has its own formulary (its list of covered drugs) with tiers, and both coverage and tier can change from plan to plan and year to year. That’s why two people on the same drug can pay very different amounts. The simplest way to know where you stand is to check the drug list for any plan you’re considering. Our Formulary Lookup lets you see whether Humira is covered, what tier it’s on, and whether any restrictions apply.
Coverage rules to expect
With a specialty biologic like Humira, a few utilization rules are common. They don’t mean the drug isn’t covered — they’re hoops the plan may ask you to clear first:
- Prior authorization. This is common with Humira. Your plan will likely need your doctor to submit medical documentation confirming the drug is appropriate for your condition before it’s covered. We explain this in more detail in what prior authorization is.
- Step therapy with a biosimilar. Some plans ask you to try a lower-cost adalimumab biosimilar first, and will only cover Humira itself if that doesn’t work well enough for you. That’s a form of step therapy.
- Quantity limits. A plan may cover only a set amount per fill or period without an approved exception.
Which of these apply depends entirely on the plan, so it’s worth checking rather than assuming.
Coverage exceptions and appeals
If your plan won’t cover Humira, requires a biosimilar you can’t tolerate, or places it on a tier that feels steep, you’re not stuck. You and your prescriber can request a coverage exception — for example, to cover Humira when the plan prefers a biosimilar, or to lower the tier. Your doctor typically explains the medical reason you need Humira specifically. If the request is denied, you have appeal rights and can ask the plan to take another look. These steps are routine, and your doctor’s office handles them often.
Alternatives to discuss with your doctor
I’m an insurance agent, not a physician, so I’d never tell you to start, stop, or switch a medication — that’s a conversation for you and your doctor. But it helps to know what the options look like.
If cost or coverage is a hurdle, your doctor might talk with you about adalimumab biosimilars, which often sit on lower tiers, or other biologics that treat the same conditions. Drugs like Enbrel and Rinvoq are sometimes part of that conversation. Whether any alternative is right for you is strictly a medical decision — your doctor knows your history and what you’ve already tried.
The $2,000 cap is real protection
For anyone on a specialty drug, this is the most important change to know about. In 2026, Part D has a $2,000 out-of-pocket maximum for the year. Once your out-of-pocket spending on covered drugs reaches $2,000, you pay nothing more for your covered prescriptions for the rest of the calendar year.
That cap is especially meaningful for a specialty biologic like Humira, where a single month’s cost can be high. There’s also a free option to spread that $2,000 into smoother monthly payments across the year, so a big bill early on doesn’t have to land all at once. You can read more in our guide to the $2,000 drug cap.
Questions to ask your doctor
When you next talk with your prescriber, these are useful to raise:
- Is Humira the best biologic for my condition, or would a biosimilar work just as well for me?
- If my plan prefers a biosimilar, are you comfortable with that switch?
- If my plan requires prior authorization or step therapy, can you help with the paperwork?
- Are there other biologics worth considering based on my history?
How to see your real cost
The best way to stop guessing is to look at your own situation. Run Humira — along with your other medications — through the Drug Cost Calculator to estimate what you’d pay across the year under a given plan, and pair it with the Formulary Lookup to confirm coverage and tier.
If you’d like help comparing plans with Humira in mind, that’s exactly what I do for folks here in Utah. Reach out through the contact page and we’ll walk through it together — no pressure, no cost, just a clear answer.
Medical & coverage disclaimer: This article is general education — not medical advice or a guarantee of coverage. Whether a specific drug is covered, and what you’ll pay, depends on your individual Part D or Medicare Advantage plan, its formulary, and the plan year, and can change. Always confirm with your plan or a licensed agent, and talk to your doctor about your treatment.